Trinity Biotech reported $105.16M in Assets for its fiscal quarter ending in December of 2025.





Assets Change Date
Abbott USD 110.43B 23.72B Mar/2026
Bayer EUR 107.94B 3.4B Mar/2026
Bio-Rad Laboratories USD 10.25B 462M Jun/2026
EDAP TMS EUR 72.06M 10.6M Mar/2026
J&J USD 201.06B 167M Jun/2026
Mesa Laboratories USD 434.85M 4.5M Dec/2025
OraSure Technologies USD 360.55M 18.62M Jun/2026
Plus Therapeutics USD 19.92M 3.59M Mar/2026
Roche Holding CHF 98.2B 2.5B Jun/2026
Siemens EUR 167.54B 428M Jun/2026
Thermo Fisher Scientific USD 113.17B 107M Jun/2026
Tosoh JPY 1.47T 59.99B Jun/2026
Trinity Biotech USD 105.16M 1.45M Dec/2025
Veracyte USD 1.49B 49.97M Jun/2026